Product Description
Exenatide is used along with diet and exercise to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in adults (Byetta) and in adults and children 10 years of age and older (Bydureon BCISE). Exenatide is in a class of medications called incretin mimetics. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Exenatide also slows the emptying of the stomach and causes a decrease in appetite. Exenatide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Exenatide is not used instead of insulin to treat people with diabetes who need insulin. (Sourced from: https://medlineplus.gov/druginfo/meds/a605034.html)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes
Known Adverse Events: Headache | Pruritus | Constipation | Diarrhea | Dyspepsia | Dizziness | Hypoglycemia | Asthenia | Injuries/wounds Unspecified
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 9
Highest Development Phases
Phase 2: Congenital Hyperinsulinism|Diabetes, Gestational|Hypopituitarism|Type 1 Diabetes|Type 2 Diabetes
Phase 1: Obesity|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LIBERATE-1 | P1 |
Not yet recruiting |
Overweight|Obesity |
2025-08-01 |
|
| 2020-004115-27 | P2 |
Active, not recruiting |
Hypopituitarism |
2024-05-06 |
|
| BetaFIT | P2 |
Active, not recruiting |
Type 1 Diabetes |
2023-09-06 |
|
| GLP1-honeymoon | P2 |
Active, not recruiting |
Type 1 Diabetes |
2020-04-15 |